MBX Biosciences, Inc. Common Stock (MBX)의 가격은 얼마입니까?

MBX Biosciences, Inc. Common Stock (MBX)의 가격은 $67.63입니다.

MBX Biosciences, Inc. Common Stock (MBX)의 시가 총액은 무엇입니까?

MBX Biosciences, Inc. Common Stock (MBX)의 시가 총액은 $3.22B입니다.

MBX Biosciences, Inc. Common Stock (MBX) PSR

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

연도	P/S 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/S 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/S 비율	P/S 비율 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Moderna, Inc. MRNA.US	11.28	-	US
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH

회사

P/S 비율

P/S 비율 차이

국가